Other Viruses Citation List: November 23 - December 6, 2012
FIV
1. Prostratin Exhibits Both Replication Enhancing and Inhibiting Effects on FIV Infection of Feline CD4(+) T-cells. Chan, C.N., E.L. McMonagle, M.J. Hosie, and B.J. Willett. Virus Research, 2012. [Epub ahead of print]; PMID[23201205].
[PubMed] OV_1123-120612.
Hepatitis B Virus
2. Randomized Trial of Lamivudine, Adefovir, and the Combination in HBeAg-Positive Chronic Hepatitis B. He, Z., J. Wang, K. Liu, H. Huang, Y. Du, Z. Lin, M. Cai, and X. Feng. Clinics and Research in Hepatology and Gastroenterology, 2012. 36(6): p. 592-597; PMID[23069315].
[PubMed] OV_1123-120612.
3. Anti-Hepatitis B Virus Activities of α-DDB-FNC, a Novel Nucleoside-biphenyldicarboxylate Compound in Cells and Ducks, and Its Anti-Immunological Liver Injury Effect in Mice. Yang, Q., X. Zhao, L. Zang, X. Fang, J. Zhao, X. Yang, Q. Wang, L. Zheng, and J. Chang. Antiviral Research, 2012. 96(3): p. 333-339; PMID[23098744].
[PubMed] OV_1123-120612.
Hepatitis C Virus
4. Hyaluronic acid-gold Nanoparticle/Interferon α Complex for Targeted Treatment of Hepatitis C Virus Infection. Lee, M.Y., J.A. Yang, H.S. Jung, S. Beack, J.E. Choi, W. Hur, H. Koo, K. Kim, S.K. Yoon, and S.K. Hahn. ACS Nano, 2012. 6(11): p. 9522-9531; PMID[23092111].
[PubMed] OV_1123-120612.
5. Synthesis, Evaluation of anti-HIV-1 and anti-HCV Activity of Novel 2',3'-Dideoxy-2',2'-difluoro-4'-azanucleosides. Martinez-Montero, S., S. Fernandez, Y.S. Sanghvi, E.A. Theodorakis, M.A. Detorio, T.R. McBrayer, T. Whitaker, R.F. Schinazi, V. Gotor, and M. Ferrero. Bioorganic & Medicinal Chemistry, 2012. 20(23): p. 6885-93; PMID[23085031].
[PubMed] OV_1123-120612.
6. Development of Potent Macrocyclic Inhibitors of Genotype 3A HCV NS3/4A Protease. Rudd, M.T., J.A. McCauley, J.J. Romano, J.W. Butcher, K. Bush, C.J. McIntyre, K.T. Nguyen, K.F. Gilbert, T.A. Lyle, M.K. Holloway, B.L. Wan, J.P. Vacca, V. Summa, S. Harper, M. Rowley, S.S. Carroll, C. Burlein, J.M. Dimuzio, A. Gates, D.J. Graham, Q. Huang, S.W. Ludmerer, S. McClain, C. McHale, M. Stahlhut, C. Fandozzi, A. Taylor, N. Trainor, D.B. Olsen, and N.J. Liverton. Bioorganic & Medicinal Chemistry Letters, 2012. 22(23): p. 7201-7206; PMID[23021993].
[PubMed] OV_1123-120612.
7. Development of Macrocyclic Inhibitors of HCV NS3/4A Protease with Cyclic Constrained P2-P4 Linkers. Rudd, M.T., C.J. McIntyre, J.J. Romano, J.W. Butcher, M.K. Holloway, K. Bush, K.T. Nguyen, K.F. Gilbert, T.A. Lyle, N.J. Liverton, B.L. Wan, V. Summa, S. Harper, M. Rowley, J.P. Vacca, S.S. Carroll, C. Burlein, J.M. Dimuzio, A. Gates, D.J. Graham, Q. Huang, S.W. Ludmerer, S. McClain, C. McHale, M. Stahlhut, C. Fandozzi, A. Taylor, N. Trainor, D.B. Olsen, and J.A. McCauley. Bioorganic & Medicinal Chemistry Letters, 2012. 22(23): p. 7207-7213; PMID[23084906].
[PubMed] OV_1123-120612.
8. Synthetic Lipophilic Antioxidant BO-653 Suppresses HCV Replication. Yasui, F., M. Sudoh, M. Arai, and M. Kohara. Journal of Medical Virology, 2012. [Epub ahead of print]; PMID[23192857]. [PubMed] OV_1123-120612.
9. Identification of Hepatitis C Virus Inhibitors Targeting Different Aspects of Infection Using a Cell-based Assay. Yu, X., B. Sainz, Jr., P.A. Petukhov, and S.L. Uprichard. Antimicrobial Agents and Chemotherapy, 2012. 56(12): p. 6109-6120; PMID[22948883].
[PubMed] OV_1123-120612.
Citations from the ISI Web of Knowledge Listings for O.V.
10. Divergent Antiviral Effects of Bioflavonoids on the Hepatitis C Virus Life Cycle. Khachatoorian, R., V. Arumugaswami, S. Raychaudhuri, G.K. Yeh, E.M. Maloney, J. Wang, A. Dasgupta, and S.W. French. Virology, 2012. 433(2): p. 346-355; ISI[000310095700008].
[WOS] OV_1123-120612.
11. Synthesis of 3',5'-cyclic Phosphate and Thiophosphate esters of 2'-C-Methyl ribonucleosides. Leisvuori, A., Z. Ahmed, M. Ora, L. Beigelman, L. Blatt, and H. Lonnberg. Helvetica Chimica Acta, 2012. 95(9): p. 1512-1520; ISI[000308718200003].
[WOS] OV_1123-120612.
12. Sesquiterpene Lactones with anti-Hepatitis C Virus Activity Using Molecular Descriptors. Rossini, M., M.T. Scotti, M.V. Correia, H.H. Fokoue, L. Scotti, F.J.B. Mendonca, M.S. da Silva, and V.D. Emerenciano. Letters in Drug Design & Discovery, 2012. 9(9): p. 881-890; ISI[000310532100011]. [WOS] OV_1123-120612.
13. PEG-IFNA/Ribavirin/Protease Inhibitor Combination Is Highly Effective in HCV-mixed Cryoglobulinemia vasculitis. Saadoun, D., S. Pol, P. Lebray, F. Blanc, G. Pialoux, A. Karras, D. Bazin, E. Plaisier, and P. Cacoub. Arthritis and Rheumatism, 2012. 64(10): p. S708-S708; ISI[000309748303378]. [WOS] OV_1123-120612.